The FDA has listed an ongoing Class II recall of a premixed vancomycin 1 g/200 mL in 5% dextrose single-dose GALAXY container by Baxter Healthcare, for current good manufacturing practice (CGMP) deviations.
A Class II recall indicates a remote probability of serious harm, and here the cause is a manufacturing-quality deviation rather than a safety problem with vancomycin itself. The action is operational: reconcile stock against the recalled lots, quarantine affected units, and make sure an alternative vancomycin preparation is available, since it is a mainstay for serious Gram-positive and suspected MRSA infection.
- An ongoing Class II recall affects a premixed vancomycin 1 g/200 mL product.
- The reason is manufacturing (CGMP) deviations, not a safety signal about vancomycin.
- Check pharmacy and ward stock against the recalled lots and quarantine affected units.
- Ensure an alternative vancomycin preparation is available for serious infections.
Why it matters
Vancomycin is a first-line agent for serious Gram-positive infection, so a supply recall is an operational risk even when the drug is unaffected.
Don't overread it
A Class II CGMP recall is a manufacturing-quality action for specific lots, not evidence of harm from vancomycin as a medicine.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free